OPRK1 and irritable bowel syndrome: Nevertheless, peripherally restricted KOR agonists such as asimadoline have been investigated in clinical trials for IBS, showing promise in managing visceral pain and bowel symptoms, particularly in diarrhea-predominant IBS, without CNS liabilities (Mangel et al., 2008).